JP7407511B2 - ＩＬ－２Ｒβ選択的作動薬と長時間作用型ＩＬ－１５作動薬との併用 - Google Patents

ＩＬ－２Ｒβ選択的作動薬と長時間作用型ＩＬ－１５作動薬との併用 Download PDF

Info

Publication number
JP7407511B2
JP7407511B2 JP2018517898A JP2018517898A JP7407511B2 JP 7407511 B2 JP7407511 B2 JP 7407511B2 JP 2018517898 A JP2018517898 A JP 2018517898A JP 2018517898 A JP2018517898 A JP 2018517898A JP 7407511 B2 JP7407511 B2 JP 7407511B2
Authority
JP
Japan
Prior art keywords
cancer
acting
agonist
long
daltons
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018517898A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018530568A5 (enExample
JP2018530568A (ja
Inventor
デボラ エイチ． チャリッチ，
ピーター カーク，
Original Assignee
ネクター セラピューティクス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ネクター セラピューティクス filed Critical ネクター セラピューティクス
Publication of JP2018530568A publication Critical patent/JP2018530568A/ja
Publication of JP2018530568A5 publication Critical patent/JP2018530568A5/ja
Application granted granted Critical
Publication of JP7407511B2 publication Critical patent/JP7407511B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2018517898A 2015-10-08 2016-10-07 ＩＬ－２Ｒβ選択的作動薬と長時間作用型ＩＬ－１５作動薬との併用 Active JP7407511B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562239207P 2015-10-08 2015-10-08
US62/239,207 2015-10-08
PCT/US2016/056088 WO2017062832A1 (en) 2015-10-08 2016-10-07 Combination of an il-2rbeta-selective agonist and a long-acting il-15 agonist

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021016606A Division JP2021066748A (ja) 2015-10-08 2021-02-04 ＩＬ−２Ｒβ選択的作動薬と長時間作用型ＩＬ−１５作動薬との併用

Publications (3)

Publication Number Publication Date
JP2018530568A JP2018530568A (ja) 2018-10-18
JP2018530568A5 JP2018530568A5 (enExample) 2019-11-14
JP7407511B2 true JP7407511B2 (ja) 2024-01-04

Family

ID=57249859

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018517898A Active JP7407511B2 (ja) 2015-10-08 2016-10-07 ＩＬ－２Ｒβ選択的作動薬と長時間作用型ＩＬ－１５作動薬との併用
JP2021016606A Withdrawn JP2021066748A (ja) 2015-10-08 2021-02-04 ＩＬ−２Ｒβ選択的作動薬と長時間作用型ＩＬ−１５作動薬との併用
JP2023085387A Withdrawn JP2023099731A (ja) 2015-10-08 2023-05-24 ＩＬ－２Ｒβ選択的作動薬と長時間作用型ＩＬ－１５作動薬との併用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021016606A Withdrawn JP2021066748A (ja) 2015-10-08 2021-02-04 ＩＬ−２Ｒβ選択的作動薬と長時間作用型ＩＬ−１５作動薬との併用
JP2023085387A Withdrawn JP2023099731A (ja) 2015-10-08 2023-05-24 ＩＬ－２Ｒβ選択的作動薬と長時間作用型ＩＬ－１５作動薬との併用

Country Status (10)

Country Link
US (1) US12233104B2 (enExample)
EP (1) EP3359182B1 (enExample)
JP (3) JP7407511B2 (enExample)
KR (1) KR102861230B1 (enExample)
CN (1) CN108135978A (enExample)
AU (1) AU2016335860B2 (enExample)
IL (1) IL258456B (enExample)
MA (1) MA47290A (enExample)
MX (1) MX2018004296A (enExample)
WO (1) WO2017062832A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119700941A (zh) * 2017-05-15 2025-03-28 尼克塔治疗公司 长效白细胞介素-15受体激动剂以及相关免疫治疗组合物和方法
WO2020247388A2 (en) 2019-06-03 2020-12-10 Medikine, Inc. Il-2alpha receptor subunit binding compounds
WO2023133595A2 (en) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010514770A (ja) 2006-12-27 2010-05-06 ネクター セラピューティックス エイエル，コーポレイション 解離可能な連結を有する第ｉｘ因子部分−ポリマー共役体
WO2015125159A1 (en) 2014-02-21 2015-08-27 Nektar Therapeutics (India) Pvt. Ltd. Il-2rbeta-selective agonists in combination with an anti-ctla-4 antibody or an an anti-pd-1 antibody

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4401756A (en) 1981-04-14 1983-08-30 Immunex Corporation Process for preparing human interleukin 2
US4569790A (en) 1984-03-28 1986-02-11 Cetus Corporation Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions
US5116943A (en) 1985-01-18 1992-05-26 Cetus Corporation Oxidation-resistant muteins of Il-2 and other protein
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
JP2524586B2 (ja) 1985-06-26 1996-08-14 シタス コーポレイション ポリマ−接合を利用する医薬組成物用蛋白質の可溶化
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4705848A (en) 1986-06-02 1987-11-10 International Minerals & Chemical Corp. Isolation of bioactive, monomeric growth hormone
US5078997A (en) 1988-07-13 1992-01-07 Cetus Corporation Pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers
US5089261A (en) 1989-01-23 1992-02-18 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US4902502A (en) 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US5153310A (en) 1989-02-28 1992-10-06 Du Pont Merck Pharmaceutical Company Il-2 analogs containing n-linked glycosylation sites
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
IE912365A1 (en) 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US6077519A (en) * 1993-01-29 2000-06-20 University Of Pittsburgh Methods for isolation and use of T cell epitopes eluted from viable cells in vaccines for treating cancer patients
CN1103815C (zh) * 1993-11-12 2003-03-26 吉里德科学公司 凝血酶突变体
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5635597A (en) 1994-05-27 1997-06-03 Affymax Technologies, N.V. Peptides that bind IL-2 receptors
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5795966A (en) 1995-02-22 1998-08-18 Immunex Corp Antagonists of interleukin-15
US7008624B1 (en) 1995-02-22 2006-03-07 Immunex Corporation Antagonists of interleukin-15
US6034072A (en) 1997-02-10 2000-03-07 Genemedicine, Inc. IL-2 gene expression and delivery systems and uses
US6180095B1 (en) 1997-12-17 2001-01-30 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
EP1411075B1 (en) 1998-03-12 2008-07-02 Nektar Therapeutics Al, Corporation Method for preparing polymer conjugates
DZ2788A1 (fr) 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
US6168785B1 (en) 1998-07-16 2001-01-02 Institut Pasteur Biological applications of new peptides of IL-2 and derivatives and use as therapeutic agents
AU2001238595A1 (en) 2000-02-22 2001-09-03 Shearwater Corporation N-maleimidyl polymer derivatives
US6689353B1 (en) 2000-06-28 2004-02-10 Bayer Pharmaceuticals Corporation Stabilized interleukin 2
ATE427318T1 (de) 2000-09-14 2009-04-15 Beth Israel Hospital Modulierung von il-2 und il-15 vermittelten t zellantworten
CN101584867A (zh) 2000-10-31 2009-11-25 瑟莫迪克斯药品公司 提高生物活性分子传递的方法和组合物
FR2826365B1 (fr) 2001-06-20 2003-09-26 Oreal Compositions cosmetiques photoprotectrices contenant des derives amides, sulfonamides ou carbamates aromatiques d'acrylonitrile et nouveaux derives amides, sulfonamides ou carbamates d'acrylonitrile
EP1546235B1 (en) 2002-09-09 2021-10-20 Nektar Therapeutics Water-soluble polymer alkanals
TWI364295B (en) 2002-12-26 2012-05-21 Mountain View Pharmaceuticals Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
ATE444984T1 (de) 2002-12-31 2009-10-15 Nektar Therapeutics Al Corp Hydrolysestabile maleimidendgruppen-enthaltende polymere
DE602004029646D1 (en) 2003-01-06 2010-12-02 Nektar Therapeutics San Carlos Thiolselektive wasserlösliche polymerderivate
EP1620118B1 (en) 2003-04-08 2014-06-18 Yeda Research And Development Co., Ltd. Reversible pegylated drugs
KR101128320B1 (ko) 2003-05-23 2012-04-12 넥타르 테라퓨틱스 아미도카르보네이트 연결기를 갖는 ｐｅｇ 유도체
US7569215B2 (en) 2003-07-18 2009-08-04 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
US20050069521A1 (en) * 2003-08-28 2005-03-31 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of interleukin-2 proteins
WO2005030196A2 (en) 2003-09-25 2005-04-07 Zymogenetics, Inc. Methods of treating autoimmune diseases using il-21
US9539337B2 (en) 2003-12-10 2017-01-10 Nektar Therapeutics Compositions comprising two different populations of polymer-active agent conjugates
US20060057102A1 (en) 2004-08-11 2006-03-16 Zheng Xin X Mutant interleukin-15-containing compositions and suppression of an immune response
AU2005335217A1 (en) 2004-10-05 2007-02-15 Ochsner Clinic Foundation Enhancement of B cell proliferation by IL-15
PL1688146T3 (pl) 2005-02-07 2007-12-31 Novartis Vaccines & Diagnostics Inc Przygotowywanie aldesleukiny do zastosowania farmaceutycznego
JP4560629B2 (ja) * 2005-03-31 2010-10-13 国立大学法人 筑波大学 腫瘍壊死誘導療法の抗腫瘍効果増強剤
US20060257361A1 (en) * 2005-04-12 2006-11-16 Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services Novel form of interleukin-15, Fc-IL-15, and methods of use
EP2390267B1 (en) 2005-06-07 2013-06-05 ESBATech - a Novartis Company LLC Stable and soluble antibodies inhibiting TNF(alpha)
WO2006138572A2 (en) 2005-06-16 2006-12-28 Nektar Therapeutics Al, Corporation Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates
US8293869B2 (en) 2005-12-16 2012-10-23 Nektar Therapeutics Polymer conjugates of GLP-1
AU2006328943B2 (en) * 2005-12-21 2011-07-21 Sentoclone International Ab Improved method for expansion of tumour-reactive T-lymphocytes for immunotherapy of patients with cancer
WO2007117685A2 (en) 2006-04-07 2007-10-18 Nektar Therapeutics Al, Corporation Conjugates of an anti-tnf-alpha antibody
CN101104077A (zh) 2006-07-12 2008-01-16 北京紫辰医药生物技术研究所 重组人白介素-2与聚乙二醇的偶合物
WO2008082669A2 (en) 2006-12-27 2008-07-10 Nektar Therapeutics Al, Corporation Von willebrand factor- and factor viii-polymer conjugates having a releasable linkage
EP2134181A4 (en) 2007-02-28 2011-09-28 Serina Therapeutics Inc ACTIVATED POLYOXAZOLINES AND COMPOSITION COMPRISING THE SAME
JP5588354B2 (ja) 2008-02-01 2014-09-10 アセンディス ファーマ エー／エス 自己切断可能なリンカーを含むプロドラッグ
KR20090103209A (ko) 2008-03-27 2009-10-01 (주)한국비엠아이 사람 인터루킨-2 동종체
WO2009135031A1 (en) * 2008-04-30 2009-11-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Substituted il-15
CA2723821C (en) 2008-05-16 2017-05-02 Nektar Therapeutics Conjugates of a cholinesterase moiety and a polymer
US8575102B2 (en) 2008-08-01 2013-11-05 Nektar Therapeutics Conjugates having a releasable linkage
US20110166063A1 (en) 2008-09-19 2011-07-07 Nektar Therapeutics Polymer conjugates of therapeutic peptides
US9274122B2 (en) 2008-10-21 2016-03-01 Baxalta Incorporated Methods for determining active ingredients in pro-drug PEG protein conjugates with releasable PEG reagents (in vitro de-pegylation)
KR102172133B1 (ko) 2010-07-30 2020-11-02 박스알타 인코퍼레이티드 옥심 결합용 친핵성 촉매
CN103517718A (zh) * 2010-11-12 2014-01-15 尼克塔治疗公司 Il-2部分与聚合物的缀合物
WO2013020079A2 (en) * 2011-08-04 2013-02-07 Nektar Therapeutics Conjugates of an il-11 moiety and a polymer
US20150017120A1 (en) 2013-06-13 2015-01-15 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-pk il-2 and adoptive cell therapy
MA39711A (fr) 2014-04-03 2015-10-08 Nektar Therapeutics Conjugués d'une fraction d'il-15 et d'un polymère

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010514770A (ja) 2006-12-27 2010-05-06 ネクター セラピューティックス エイエル，コーポレイション 解離可能な連結を有する第ｉｘ因子部分−ポリマー共役体
WO2015125159A1 (en) 2014-02-21 2015-08-27 Nektar Therapeutics (India) Pvt. Ltd. Il-2rbeta-selective agonists in combination with an anti-ctla-4 antibody or an an anti-pd-1 antibody

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Ｓｈｉｂａｔａ Ｈ ｅｔ ａｌ．，Ｏｐｔｉｍｉｚａｔｉｏｎ ｏｆ ｐｒｏｔｅｉｎ ｔｈｅｒａｐｉｅｓ ｂｙ ｐｏｌｙｍｅｒ－ｃｏｎｊｕｇａｔｉｏｎ ａｓ ａｎ ｅｆｆｅｃｔｉｖｅ ＤＤＳ，Ｍｏｌｅｃｕｌｅｓ，２００５年，Ｖｏｌ．１０， Ｎｏ．１，ｐ．１６２－１８０，ｄｏｉ：１０．３３９０／１００１０１６２
Ｗｅｉ Ｃ ｅｔ ａｌ．，Ｔｈｅ ＣＩＫ ｃｅｌｌｓ ｓｔｉｍｕｌａｔｅｄ ｗｉｔｈ ｃｏｍｂｉｎａｔｉｏｎ ｏｆ ＩＬ－２ ａｎｄ ＩＬ－１５ ｐｒｏｖｉｄｅ ａｎ ｉｍｐｒｏｖｅｄ ｃｙｔｏｔｏｘｉｃ ｃａｐａｃｉｔｙ ａｇａｉｎｓｔ ｈｕｍａｎ ｌｕｎｇ ａｄｅｎｏｃａｒｃｉｎｏｍａ，Ｔｕｍｏｒ Ｂｉｏｌｏｇｙ，２０１４年，Ｖｏｌ．３５， Ｎｏ．３，ｐ．１９９７－２００７，ｄｏｉ：１０．１００７／ｓ１３２７７－０１３－１２６５－２２．

Also Published As

Publication number Publication date
EP3359182A1 (en) 2018-08-15
US12233104B2 (en) 2025-02-25
EP3359182B1 (en) 2023-04-19
MA47290A (fr) 2019-11-27
US20180296645A1 (en) 2018-10-18
KR20180063184A (ko) 2018-06-11
JP2018530568A (ja) 2018-10-18
CA3000211A1 (en) 2017-04-13
WO2017062832A1 (en) 2017-04-13
IL258456A (en) 2018-06-28
AU2016335860A1 (en) 2018-04-12
JP2023099731A (ja) 2023-07-13
AU2016335860B2 (en) 2023-08-10
IL258456B (en) 2021-07-29
KR102861230B1 (ko) 2025-09-17
HK1253347A1 (en) 2019-06-14
CN108135978A (zh) 2018-06-08
MX2018004296A (es) 2018-08-01
JP2021066748A (ja) 2021-04-30

Similar Documents

Publication Publication Date Title
US10786552B2 (en) Il-2Rβ-selective agonists in combination with an anti-CTLA-4 antibody or an anti-PD-1 antibody
JP2023099731A (ja) ＩＬ－２Ｒβ選択的作動薬と長時間作用型ＩＬ－１５作動薬との併用
US11318164B2 (en) Immunotherapeutic treatment method using an interleukin-2 receptor beta-selective agonist in combination with adoptive cell transfer therapy
KR20190105568A (ko) 종양의 면역 요법적 치료 방법
EP3930747A1 (en) Immunotherapeutic combination for treating cancer
US20210154277A1 (en) Immunotherapeutic combination for treating cancer
CA3000211C (en) Combination of an il-2rbeta-selective agonist and a long-acting il-15 agonist
HK1253347B (en) Combination of an il-2rbeta-selective agonist and a long-acting il-15 agonist
HK40056474A (en) Il-2rbeta-selective agonists in combination with an anti-pd-1 antibody

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191003

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191003

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200904

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210204

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210802

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211129

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20211129

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20211207

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20211208

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20220304

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20220308

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20221114

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20230404

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230915

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231017

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231219

R150 Certificate of patent or registration of utility model

Ref document number: 7407511

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150